denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Sponsor: Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Legend Biotech
Program: Friday Satellite Symposia
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Practice (Health Services and Quality), Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diversity, Equity, and Inclusion (DEI), Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events
Hematology Disease Topics & Pathways:
Research, Clinical trials, Clinical Practice (Health Services and Quality), Clinical Research, Chimeric Antigen Receptor (CAR)-T Cell Therapies, Diversity, Equity, and Inclusion (DEI), Diseases, Treatment Considerations, Biological therapies, Immunotherapy, Adverse Events
Friday, December 6, 2024: 3:00 PM-6:00 PM
Room 6B
(San Diego Convention Center)
Chair:
Jesus G Berdeja, MD, The Greco-Hainsworth Tennessee Oncology Centers for Research
Disclosures:
Berdeja: Janssen: Honoraria, Speakers Bureau; 2 Seventy Bio; AbbVie; Amgen; BMS; C4 Therapeutics; Caribou Biosciences; CARsgen; Cartesian Therapeutics; Celularity; CRISPR Therapeutics; Fate Therapeutics; Genentech; GSK; Ichnos Sciences; Incyte; Janssen; Juno Therapeutics; K36 Therapeutics; Karyopharm: Research Funding; AstraZeneca; BMS; Caribou Biosciences; Galapagos; Janssen; K36 Therapeutics; Kite Pharma; Legend Biotech; Pfizer; Regeneron; Roche; Sanofi-Aventis; Sebia; Takeda: Consultancy.
Speaker:
Adriana Rossi, MD, MSc, Mount Sinai
Disclosures:
Rossi: Adaptive, BMS, Janssen, Karyopharm, JNJ, and Sanofi: Consultancy.
A few years after their emergence, CAR T-cell therapies continue to revolutionize the management of multiple myeloma. Recently, data has emerged about the benefits of and rationale for using CAR T-cell therapies in earlier lines of myeloma therapy. Despite this, some clinicians still hesitate to recommend CAR T-cell therapies to their patients due to misconceptions about the complexity of care management with these therapies. This session aims to bust those myths and get attendees up to speed on the latest data and practical use of CAR T-cell therapies in myeloma care. CAR T-cell therapy experts will discuss and debate their recommended approaches to identifying appropriate patients for CAR T-cell therapy. The dynamic duo will present best practices for optimizing the treatment journey, including strategies for bridging therapies and selecting and sequencing treatment. The discussion will also touch upon key adverse event management considerations, how to optimize treatment in the community setting, and approaches for improving diversity, equity, and inclusion (DEI) in myeloma care.
Engage with faculty in a closing live Q&A session to clarify your challenges in using CAR T-cell therapy in clinical practice. Don't miss this 60-minute whirlwind through CAR T-cell therapy best practices!
See more of: Friday Satellite Symposia